TITLE

Familial antithrombin-III deficiency during cardiopulmonary bypass: a case report

AUTHOR(S)
Brinks, H. J.; Weerwind, P. W.; Verkroost, M. W. A.; Nováková, I.; Brouwer, M. H. J.
PUB. DATE
October 2000
SOURCE
Perfusion;Oct2000, Vol. 15 Issue 6, p553
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The serine protease inhibitor antithrombin-III (AT-III) is the principal in vivo inhibitor of blood coagulation, inactivating mainly thrombin, but also other serine proteases. Binding of AT-III to heparin dramatically increases its inhibitory effect. AT-III deficiency during cardiopulmonary bypass (CPB) can lead to insufficient anticoagulation which cannot be treated by higher doses of heparin. A 60-year-old male with familial AT-III deficiency was admitted to our hospital for coronary artery bypass surgery and aortic valve replacement. Four days before the operation, acenocoumarol was stopped and anti-X[sub a] nadroparincalcium (Fraxiparine) was started. AT-III activity at that time was 56%. Two hours before the operation, a single dose of 4500 IU AT-III concentrate was administered. Heparinization was performed with 400 IU/kg of porcine mucosal heparin, increasing the activated coagulation time (ACT) from a baseline of 115 to 549 s. AT-III activity at that time was above 100% and the plasma D-dimer concentration was 230 ng/l. ACTs during CPB remained above 999 s, whereas the AT-III activity dropped to 54% and the D-dimer increased up to 500 ng/l at the end of CPB. CPB was terminated uneventfully. Heparin was reversed with 3 mg/kg protamine chloride, decreasing the ACT to 155 s. In the intensive care unit (ICU), the patient received prophylactic Fraxiparine and 1500 IU AT-III, increasing the AT-III activity to 84%. Postoperatively, there was continued blood loss, which necessitated the administration of whole blood and eventually re-exploration. The case presented illustrates an uneventful treatment of a patient with a hereditary AT-III deficiency undergoing CPB. In spite of an uneventful treatment with AT-III pre-CPB, administration of prophylactic AT-III concentrate after surgery should be considered with caution, as this might increase the postoperative morbidity.
ACCESSION #
4747973

 

Related Articles

  • Argatroban.  // Reactions Weekly;8/10/2013, Issue 1465, p9 

    An abstract of the article "Difficulty in the management of anticoagulation with argatroban during off-pump coronary artery bypass grafting," by K. Matsuyama and colleagues is presented.

  • Plasma Levels of Heparin Cofactor II (HCII) and Thrombin-HCII Complex in Patients with Disseminated Intravascular Coagulation. Noda, Ayako; Wada, Hideo; Kusiya, Fumihiko; Sakakura, Miho; Onishi, Katsuya; Nakatani, Kaname; Gabazza, Esteban C.; Asahara, Naomi; Tsukada, Minoru; Nobori, Tsutomu; Shiku, Hiroshi // Clinical & Applied Thrombosis/Hemostasis;Jul2002, Vol. 8 Issue 3, p265 

    Plasma levels of heparin cofactor II (HCII), thromhin-HCII complex (THC), antithrombin (AT), and thrombin-AT complex (TAT) were evaluated in patients with disseminated intravascular coagulation (DIC) associated with several underlying diseases. Plasma levels of AT were significantly reduced in...

  • Coronary artery surgery: cardiotomy suction or cell salvage? Lau, Kelvin; Shah, Hetul; Kelleher, Andrea; Moat, Neil // Journal of Cardiothoracic Surgery;2007, Vol. 2, p1 

    Coronary artery bypass grafting (CABG) today results in what may be regarded as acceptable levels of blood loss with many institutions avoiding allogeneic red cell transfusion in over 60% of their patients. The majority of cardiac surgeons employ cardiotomy suction to preserve autologous blood...

  • Pathophysiological aspects of cardiotomy suction usage. Svitek, Vladimir; Lonsky, Vladimir; Anjum, Faraz // Perfusion;May2010, Vol. 25 Issue 3, p147 

    Cardiotomy suction is used for preservation of autologous blood during on-pump cardiac surgery at present. Controversially, the exclusion of cardiotomy suction in some types of operations (coronary artery bypass surgery) is not necessarily associated with an increased transfusion requirement. On...

  • disseminated intravascular coagulation.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p673 

    A definition of the term "disseminated intravascular coagulation" is presented. It refers to a life-threatening disease occurring as a complication of other conditions in which the coagulation pathways are hyperstimulated, resulting in diffuse rather than localized activation of coagulation...

  • Recombinant Human Antithrombin III: rhATIII. Adis International Limited // Drugs in R&D;2004, Vol. 5 Issue 2, p110 

    GTC Biotherapeutics (formerly Genzyme Transgenics Corporation) is developing a transgenic form of antithrombin III known as recombinant human antithrombin III [rhA TIll]. It is produced by inserting human DNA into the cells of goats so that the targeted protein is excreted in the milk of the...

  • Antithrombin III in Shock and Disseminated Intravascular Coagulation. Vinazzer, Helmut A. // Clinical & Applied Thrombosis/Hemostasis;Winter1995, Vol. 1 Issue 1, p62 

    Antithombin III (AT III) is the physiological inhibitor of a series of activated clotting factors. Its diminution increases the tendency of thromboembolism. In cases of acute DIC, AT III binds to thrombin and to other activated factors in circulation. Thereby both partners of the reaction become...

  • Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery. Solomon, C.; Budde, U.; Schneppenheim, S.; Czaja, E.; Hagl, C.; Schoechl, H.; von Depka, M.; Rahe-Meyer, N. // BJA: The British Journal of Anaesthesia;Apr2011, Vol. 106 Issue 4, p494 

    Background Aortic valve (AV) defects can destroy high molecular weight multimers (HMWM) of von Willebrand factor (VWF), leading to acquired von Willebrand syndrome (aVWS) type IIA. This syndrome is considered a cause for increased perioperative bleeding in AV surgery. If diagnosed before...

  • Hypercoagulability in patients undergoing coronary artery bypass grafting: prevalence, patient characteristics and postoperative outcome †. Rafiq, Sulman; Johansson, Pär Ingemar; Ostrowski, Sisse Rye; Stissing, Trine; Steinbrüchel, Daniel Andreas // European Journal of Cardio-Thoracic Surgery;Mar2012, Vol. 41 Issue 3, p550 

    OBJECTIVES To investigate the prevalence of preoperative hypercoagulability assessed by thromboelastography (TEG), to identify patient characteristics associated with hypercoagulability and to explore whether hypercoagulability is associated with a greater risk for myocardial infarction (MI),...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics